Calendario›REGN›Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Retinopathy of Prematurity (del registro, en inglés).

Fase

no aplica

Estado

En marcha, sin reclutar

Participantes

100

previstos

Centros

30

Fin del objetivo primario

nov 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en feb 2021.

Qué mide

Binocular best-corrected visual acuity (BCVA) (5 years of chronological age) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPrimary objectives of the study are: * To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). * To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. Secondary objectives of the study are: * To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. * To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04515524), actualizada en mar 2026.